• Overseas
  • Domestic
Deadline for Abstract Submission : May 31 (Fri), 2024 (KST)
Notification of Acceptance : August 1(Thu), 2024 (KST)

Submitted abstracts will be reviewed by the Scientific Program Committee. The presentation type may possibly be changed following review by the Scientific Committee.

Abstract submission does not constitute registration, and presenters are required to register for the conference separately. Please carefully read the guidelines before submitting your abstract.

Steps for Abstract Submission

  • Step 1 Click the Abstract Submission button
  • Step 2 Sign up or Log in
  • Step 3 Fill out Participant Info and Click “Add”
  • Step 4 Complete Abstract Submission and Author Info Section
  • Step 5 Save and Review until the submission deadline
*You can submit abstracts with the same log-in ID/PW from your participation in KSMO 2019 ~ 2023.
*After submission, you can review and modify your abstracts at 'My page-Abstract Submission’ until the submission deadline.

Abstract Submission Guidelines

  • -Please select the correct abstract type.
    Any problems or disadvantages arising from the incorrect selection of abstract type are the responsibility of the submitter.
  • Regular Abstract “Regular Abstract” refers to all types of oncology-related research that are eligible for submission.
    Trials in Progress Abstract “Trials in Progress Abstract” refers to ongoing trials that have not reached prespecified endpoints for analysis that are eligible for submission. |Trials in Progress abstracts that include results or preliminary data will be rejected without further review.

    It should be organized according to two sections: Backgrounds and Methods.
    Encore Abstract “Encore Abstract” refers to abstracts presented in another congress after September 8, 2023, but with updated data.

    • Encore submissions must have been presented solely in abstract form, including publication in conference proceedings. (Submissions which have already been published in the full publication form in journals will NOT be accepted.)

    • Include significant additional data from the previous presentation (as determined by the review committee).

    • Include the abstract title, co-authors listed, the full abstract, and indicate if this is an encore presentation and, if so, where it was previously presented. This information should be presented both in the abstract and on the poster. It is the sole responsibility of the author to follow these rules. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s).
    해외 지원 의무 초록 This type is only for KSMO Members.
  • -Abstracts must be written in clear English
  • -Abstracts should be no more than 2,600 characters including spaces for the total of abstract body. (NOT including abstract title, author names and institutions)
  • -Research work to be presented should be original and not already published as a full paper. The content of the abstract may have been presented at another prior meeting, but you are encouraged to add new information/data.
  • -An abstract should include a title, author's name and affiliation, body, and keywords.
  • Title Abstract title should be less than 30 words. Spaces do not count as characters.
    Author You can enter up to 30 authors.
    Abstract Body The abstract body text should be structured chronologically into four sections: Background, Methods, Results, and Conclusions.
    In the case of a “Trials in Progress Abstract,” it should be organized according to two sections: Background and Methods.
    Keywords 3 keywords which the first word begins with a capital letter.
    Tables and Images No tables, graphs or images are allowed.
  • -It is the responsibility of the authors to ensure that their text does not contain typos or grammatical errors.
  • -Authors have the option of choosing their presentation type (Oral presentation or E-poster). However, the Scientific Program Committee will make the final decision after review.
  • -The right to publish your abstract is granted to the KSMO 2024 Organizing Committee.
  • -Presenting authors must register for the conference through the website by August 16, 2024 (KST).

Abstract Categories

  • Discovery of Novel Targets
  • Discovery and Validation of Biomarkers
  • Molecular Targeted Therapy
  • Functional Genomics
  • Progress in Precision Medicine
  • Cutting Edge of Immuno-Oncology
  • Multidisciplinary/Multicenter Clinical Trial
  • Innovation of Clinical Trials
  • Innovative Technology in Oncology
  • Real-World Data Science
  • Regulatory Science
  • Translational Research
  • Tumor Biology
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Melanoma/Skin Cancers
  • Sarcoma
  • MUO
  • Oncology Nursing
  • Oncology Pharmacy
  • Palliative/Supportive Care
  • Miscellaneous

Notification of Acceptance

  • -All submitted abstracts will be reviewed by the Scientific Committee according to standard review procedures.
  • -Abstract acceptance will be notified by email to presenting authors on the notification date.
  • -Outstanding abstracts will receive the award! For further details, please refer to the Awards page.

Withdrawal of Abstracts

  • -If the presenting author of an accepted abstract does not register by August 16, 2024 (KST), the abstract will be automatically withdrawn from the final program.
  • -If you would like to withdraw an abstract, please notify the KSMO 2024 Secretariat (info@ksmoconference.org) by email as soon as possible.